|
AU2005235811B2
(en)
|
2004-02-06 |
2011-11-03 |
Morphosys Ag |
Anti-CD38 human antibodies and uses therefor
|
|
US9200061B2
(en)
|
2004-02-06 |
2015-12-01 |
Morpho Sys AG |
Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
|
|
US20060030003A1
(en)
*
|
2004-05-12 |
2006-02-09 |
Simon Michael R |
Composition and method for introduction of RNA interference sequences into targeted cells and tissues
|
|
US20050255120A1
(en)
*
|
2004-05-12 |
2005-11-17 |
Simon Michael R |
Composition and method for introduction of DNA directed RNA interference sequences into targeted cells and tissues
|
|
US20050260214A1
(en)
*
|
2004-05-12 |
2005-11-24 |
Simon Michael R |
Composition and method for introduction of RNA interference sequences into targeted cells and tissues
|
|
US20110110937A1
(en)
*
|
2004-05-12 |
2011-05-12 |
Simon Michael R |
Composition and method for introduction of rna interference sequences into targeted cells and tissues
|
|
US20110117088A1
(en)
*
|
2004-05-12 |
2011-05-19 |
Simon Michael R |
Composition and method for introduction of rna interference sequences into targeted cells and tissues
|
|
EP3312196B1
(en)
*
|
2005-03-23 |
2019-07-17 |
Genmab A/S |
Antibodies against cd38 for treatment of multiple myeloma
|
|
EP1888647A2
(en)
*
|
2005-05-24 |
2008-02-20 |
MorphoSys AG |
Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
|
|
PL2860192T3
(pl)
|
2005-10-12 |
2018-03-30 |
Morphosys Ag |
Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38
|
|
US20070106233A1
(en)
*
|
2005-10-20 |
2007-05-10 |
Percutaneous Systems, Inc. |
Systems and methods for dilating and accessing body lumens
|
|
JP5328018B2
(ja)
*
|
2006-06-05 |
2013-10-30 |
国立大学法人広島大学 |
抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞
|
|
WO2008033105A1
(en)
*
|
2006-09-13 |
2008-03-20 |
Dso National Laboratories |
Hemagglutinin antibody and uses thereof
|
|
AU2007302448C1
(en)
*
|
2006-09-26 |
2019-02-14 |
Genmab A/S |
Combination treatment of CD38-expressing tumors
|
|
EP2191843A1
(en)
*
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
|
|
EP2191841A1
(en)
*
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
|
EP2191842A1
(en)
*
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
|
|
EP2191840A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
|
EP2580243B1
(en)
|
2010-06-09 |
2019-10-16 |
Genmab A/S |
Antibodies against human cd38
|
|
SI2608809T1
(sl)
|
2010-08-27 |
2019-08-30 |
Gilead Biologics, Inc. |
Protitelesa proti matriksu metaloproteinaze 9
|
|
NZ607473A
(en)
|
2010-09-27 |
2014-11-28 |
Morphosys Ag |
Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
|
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
|
BR112014021081A2
(pt)
|
2012-02-29 |
2017-07-04 |
Gilead Biologics Inc |
anticorpos para a metaloproteinase da matriz 9
|
|
GB201216002D0
(en)
|
2012-09-07 |
2012-10-24 |
Deutsches Rheuma Forschungszentrum Berlin Drfz |
Compositions adn methods
|
|
ES2658953T3
(es)
|
2012-09-25 |
2018-03-13 |
Morphosys Ag |
Combinaciones y usos de los mismos
|
|
DK2914302T3
(en)
|
2012-11-05 |
2017-04-10 |
Morphosys Ag |
RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT
|
|
IL285403B2
(en)
|
2014-01-27 |
2023-10-01 |
Molecular Templates Inc |
Polypeptides that remove an epitope for MHC group I
|
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
US11142584B2
(en)
|
2014-03-11 |
2021-10-12 |
Molecular Templates, Inc. |
CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
|
|
EP3137488B1
(en)
|
2014-06-11 |
2019-01-02 |
Molecular Templates, Inc. |
Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeting molecules comprising the same
|
|
PE20170676A1
(es)
|
2014-09-09 |
2017-05-22 |
Janssen Biotech Inc |
Terapias de combinacion con anticuerpos anti-cd38
|
|
EA202092609A1
(ru)
|
2014-12-04 |
2021-10-29 |
Янссен Байотек, Инк. |
Антитела к cd38 для лечения острого миелолейкоза
|
|
KR20170110601A
(ko)
|
2015-02-05 |
2017-10-11 |
몰레큘러 템플레이츠, 인코퍼레이션. |
시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물
|
|
JP7160533B2
(ja)
|
2015-05-13 |
2022-10-25 |
モルフォシス・アーゲー |
多発性骨髄腫（ｍｍ）の処置
|
|
CA2986594C
(en)
|
2015-05-20 |
2025-06-10 |
Tufts Medical Center, Inc. |
Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
|
|
HUE051246T2
(hu)
|
2015-05-30 |
2021-03-01 |
Molecular Templates Inc |
Deimmunizált shigatoxin alegység vázak és azokat tartalmazó, sejthez irányító molekulák
|
|
CN107708734B
(zh)
|
2015-06-22 |
2022-01-11 |
詹森生物科技公司 |
用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
|
|
US20170044265A1
(en)
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
|
HUE053366T2
(hu)
|
2015-11-03 |
2021-06-28 |
Janssen Biotech Inc |
Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
|
|
US10781261B2
(en)
|
2015-11-03 |
2020-09-22 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
|
BR112018011100A2
(en)
|
2015-12-01 |
2018-12-04 |
Genmab B.V. |
antibody, composition, nucleic acid construct, expression vector, host cell, method for treating an individual having a cancer, kit of parts, and use of an antibody or composition.
|
|
CN108699161B
(zh)
|
2016-03-04 |
2022-06-03 |
莫佛塞斯公司 |
多发性骨髓瘤中m-蛋白应答的临床评估
|
|
US20190233533A1
(en)
|
2016-06-28 |
2019-08-01 |
Umc Utrecht Holding B.V. |
Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
|
|
JP7075134B2
(ja)
|
2016-12-07 |
2022-05-25 |
モレキュラー テンプレーツ，インク． |
部位特異的コンジュゲーションのための志賀毒素ａサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子
|
|
JP7082424B2
(ja)
|
2017-01-25 |
2022-06-08 |
モレキュラー テンプレーツ，インク． |
脱免疫化された志賀毒素ａサブユニットエフェクター及びｃｄ８＋ｔ細胞エピトープを含む細胞標的化分子
|
|
CN111565751A
(zh)
|
2017-10-31 |
2020-08-21 |
詹森生物科技公司 |
治疗高危多发性骨髓瘤的方法
|
|
WO2019149743A1
(en)
|
2018-01-30 |
2019-08-08 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
|
|
KR20200143634A
(ko)
|
2018-04-17 |
2020-12-24 |
몰레큘러 템플레이츠, 인코퍼레이션. |
탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
|
|
CN109265551B
(zh)
*
|
2018-09-25 |
2020-09-15 |
华东师范大学 |
Cd38抗体、嵌合抗原受体和药物
|
|
IL317328A
(en)
|
2018-12-14 |
2025-01-01 |
Morphosys Ag |
Antibody formulations
|
|
JP7687956B2
(ja)
|
2019-03-15 |
2025-06-03 |
モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物
|
|
JP2022539248A
(ja)
|
2019-07-02 |
2022-09-07 |
フレッド ハッチンソン キャンサー リサーチ センター |
組換えａｄ３５ベクター及び関連遺伝子治療改善
|
|
CA3204187A1
(en)
|
2021-01-14 |
2022-07-21 |
Stefan Steidl |
Anti-cd38 antibodies and their uses
|
|
TW202302642A
(zh)
|
2021-03-01 |
2023-01-16 |
德商莫菲西斯公司 |
用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
|
|
TW202321303A
(zh)
|
2021-07-19 |
2023-06-01 |
德商莫菲西斯公司 |
抗pla2r自體抗體媒介膜性腎病變之治療
|